Teva plots Japanese joint venture; Suisse boosts Novartis, bumps Sanofi;

> Teva Pharmaceutical Industries is in talks to set up a development and sales joint venture with Japan's Kowa as part of comprehensive effort to break into the Japanese market. Report

> Credit Suisse upgraded Novartis to "outperform" because the stock has "defensive characteristics;" meanwhile, the bank downgraded Sanofi-Aventis to "underperform," saying that it's under pressure from the possible spread of Plavix generics in Europe. Report

> Sanofi-Aventis got the FDA nod to market its Nasacort nasal spray for use in children 2-5 years. Sanofi release

> UK-based Archimedes Pharma launched its Zibor heparin product in its home market for post-operative clotting prevention. Report

> Anika Therapeutics inked an exclusive distribution agreement with a Johnson & Johnson subsidiary, under which DePuy Mitek will market Orthovisc-branded hyaluronic acid products in Latin America. Report

> Sanofi-Aventis has recalled remaining batches of its contaminated blood thinner Lovenox, a heparin product, which were distributed before May 2008. Report

> Drug delivery specialist Tris Pharma wrapped up an expansion of its New Jersey research and manufacturing building, with the addition of 15,000 square feet of space to its FDA-compliant facility. Tris release

> Canada's Angiotech Pharmaceuticals is restructuring its operations as a badly needed investment of up to $300 million appears to be in doubt now. Report

> Encorium Group, a multinational CRO, says that it is delaying a planned acquisition and will cut 18 percent of its U.S. staff. Report

> The UK's Allergy Therapeutics says that a late-stage trial of its ragweed vaccine proved positive, with a statistically significant improvement in comparison to a placebo. Report

> One of the biggest moves in biopharma this week will turn on the FDA's decision on prasugrel, a blood-clot drug advanced by Eli Lily and Daiichi Sankyo. Report

> The UK's Allergy Therapeutics says that a late-stage trial of its ragweed vaccine proved positive, with a statistically significant improvement in comparison to a placebo. Report

> OpGen was a tiny Madison, WI-based company with only five employees. Now with $220k in state and local loans and $23.6 million in financing, the Gaithersburg-based company plans to add 100 more to its 55 employees as it ramps up sales efforts. Report

> Genzyme has opened the doors to a new, 180,000-square-foot research facility in Framingham, MA that will eventually house some 350 investigators and other staffers. Report

> Investigators at the University of Wisconsin have made a key breakthrough in the use of adult stem cells to treat ALS. Report

And Finally... Alzheimer's patients who take both a cholinesterase inhibitor and memantine showed a significantly smaller rate of decline than those on no medication or a sholinesterase inhibitor alone. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.